Dengue is a mosquito-borne viral disease that has rapidly spread in all regions of the World Health Organization in recent decades. The disease is caused by any one of four related Dengue viruses and is transmitted mainly by Aedes mosquitoes. Most people who are infected experience only mild symptoms, like fever, muscle and joint pains, and headache. However, a small proportion develop severe dengue that can lead to circulatory failure and death. There are currently no specific antivirals approved for dengue treatment and management focuses on adequate fluid intake and pain management.
History of Dengue Vaccine Development
The idea of developing a Dengue Vaccines was conceived in the 1970s due to increased incidence and spread of the disease to new regions. Early vaccine candidates were monovalent and provided incomplete protection against only one of the four serotypes. In the late 1980s, attention shifted towards development of a tetravalent vaccine that provides protection against all four serotypes. However, this posed unique challenges due to the complex interactions between pre-existing immunity from prior infections or vaccination. Multiple candidates were evaluated through the 2000s but safety issues halted their development. The first dengue vaccine, CYD-TDV or Dengvaxia, was licensed in several countries in 2015 after extensive clinical trials. However, its use has been restricted due to safety concerns identified later. More candidates are currently in clinical trials with promising results.
Mechanism of Action of Dengue Vaccines
All dengue vaccine candidates aim to elicit protective antibodies against the four distinct but related serotypes using one of two main platforms - live attenuated vaccines or recombinant subunit vaccines. Live attenuated vaccines utilize weakened live virus strains that can infect and replicate in the body to induce potent immune responses similar to natural infection. Recombinant subunit vaccines consist of non-infectious viral proteins that trigger antibody production without causing illness. Both platforms aim to induce long-lasting neutralizing antibodies against all four serotypes to provide comprehensive protection. Memory B and T cell responses are also stimulated to enable a rapid anamnestic antibody response upon future natural infection or re-exposure to the vaccine.
Efficacy of Licensed Dengue Vaccine
Dengvaxia was evaluated in 25 pivotal Phase 2 and 3 efficacy trials involving over 30,000 individuals across Asia and Latin America. It demonstrated overall efficacy ranging from 56-97% against virologically confirmed dengue caused by any of the four serotypes in subjects aged 9-16 years over 25-31 months of follow-up. However, further evaluation revealed it increased the risk of severe disease in individuals not previously exposed to dengue viruses. This was attributed to antibody-dependent enhancement where non-neutralizing antibodies from the vaccine predisposed such individuals to worse outcomes upon their first natural infection. Ongoing trials are exploring the optimal way to identify and exclude such seronegative individuals.
Lessons from Dengvaxia Experience
The Dengvaxia experience highlighted several important aspects of dengue vaccine development. Tetravalent formulations pose a unique risk of antibody-dependent enhancement and safety needs to be rigorously evaluated across all age groups and serostatus. Longer term safety monitoring is critical even after licensure. Vaccine serostatus screening assays need standardization and evaluation of different booster strategies to sustain protection is vital. It underscored the value of well-designed studies to establish causal relationships between vaccine failure or adverse events. Transparency in data sharing with regulatory agencies and the scientific community is important for building trust. Finally, it exemplified that no single product or approach may suffice and continuous innovations will be needed.
Pipeline of Other Dengue Vaccine Candidates
Several other vaccine formulations are currently in Phase 1, 2 or 3 clinical trials. Takeda's TAK-003 is a live attenuated tetravalent candidate administered in two doses six months apart, showing good safety and immunogenicity so far. Butantan has developed a recombinant subunit vaccine BIBP administered thrice over one year demonstrating good efficacy against all four serotypes. The NIH developed TV003/TV005 is a chimeric yellow fever-dengue vaccine combining structural genes from wild-type dengue viruses into the yellow fever 17D backbone. Phase 3 efficacy trials are ongoing. Additionally, Moderna and Johnson & Johnson are developing mRNA and adenovirus vectored dengue vaccine candidates respectively, harnessing new vaccine platforms. Overall, the pipeline is promising and offers hope that a safe, effective and long-lasting dengue vaccine may soon be available.
Challenges to Introduction and Uptake of Dengue Vaccines
While the availability of a well-tolerated and efficacious dengue vaccine would significantly curb disease burden, several challenges remain for its successful introduction and public health impact. Access needs to be affordable and equitable globally, especially in highly-endemic developing countries. Large-scale production and steady supply must be guaranteed to meet demand. Health systems require strengthening distribution networks and training to ensure high coverage is achieved. Public awareness and community acceptance are equally important given controversy over Dengvaxia. Surveillance needs to monitor serotype distribution changes post-vaccination. Integration with existing dengue vector control efforts will optimize impact. Thus, coordinated multi-sectoral efforts will be crucial to harness the full potential of future dengue vaccines.
As the threat from dengue expands relentlessly, the development of a safe and effective vaccine offers hope. Significant progress has been made by overcoming several hurdles, with multiple candidate vaccines progressing through trials. While licensure of the first vaccine was a landmark achievement, subsequent experiences highlighted the need for continued research and evaluation. The lessons from Dengvaxia have strengthened understanding and guided further innovations. With sustained efforts, the goal of broad control of this major global health problem may be within reach in the years to come. Strong regulatory oversight and coordinated global action are essential to translate scientific advances into tangible public health benefits.
Get this Report in Japanese Language- デング熱ワクチン
Get this Report in Korean Language- 뎅기열 백신
About Author-
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
Comments
0 comment